secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2025-06-13T23:59:59+00:00
Accession:  0001140361-25-022375
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed prices $750M common stock offering at $96/share for brensocatib R&D and commercialization
--------------------------------------------------------------------------------

- Priced 7,812,500 shares at $96.00; net proceeds ~$716.3M after underwriting discounts.
- Underwriters granted 30-day option for up to 1,171,875 additional shares (~$112.5M).
- Proceeds to fund brensocatib R&D, pre-commercial/commercial, ARIKAYCE, TPIP, INS1201, and general corporate.
- Offering expected to close June 13, 2025; joint book-runners: Goldman Sachs, Leerink, BofA, Jefferies, J.P. Morgan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036125022375/0001140361-25-022375-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036125022375/ny20050461x3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-022375

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer